Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Considers Moratorium On Public Pharma Price Caps

This article was originally published in PharmAsia News

Executive Summary

Indian authorities are considering a two- or three-year reprieve from drug price controls for public-sector pharmaceutical companies. That would mean firms such as Bengal Chemicals, Hindustan Antibiotics and Indian Drug and Pharmaceuticals would not have to comply with the government-ordered caps on the price of their products. The effort to help the PSUs, which make only drugs that fall under price controls, comes in response to increases in the prices of raw materials used for drugs. Such firms also supply drugs to institutions at prices already fixed. The private pharma industry has yet to react to the proposal. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts